(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 October 2025 (23.10.2025)

WIPO | PCT

(10) International Publication Number
WO 2025/221153 A1

(51) International Patent Classification:
A61K 31/138 (2006.01) *A61K 31/675* (2006.01)
A61K 9/00 (2006.01) *A61P 35/00* (2006.01)
A61K 9/06 (2006.01)

(21) International Application Number:
PCT/NZ2025/050036

(22) International Filing Date:
16 April 2025 (16.04.2025)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2024202561 18 April 2024 (18.04.2024) AU

(71) Applicants: **AFT PHARMACEUTICALS LIMITED** [NZ/NZ]; Level 1, 129 Hurstmere Road, Takapuna, 0622 Auckland (NZ). **MASSEY VENTURES LIMITED** [NZ/NZ]; Massey University, Turitea Campus, 234 Tennent Drive, 4472 Palmerston North (NZ). **GILLIES MCINDOE RESEARCH INSTITUTE** [NZ/NZ]; 7 Hospital Road, Newtown, 6021 Wellington (NZ).

(72) Inventors: **ATKINSON, Hartley**; 16 Brett Ave, Takapuna, 0622 Auckland (NZ). **MACKAY, Sean**; 26D Andrew Young Street, 4410 Palmerston North (NZ). **GRAY, Clint**; 9 Torquay Terrace, Newtown, 6021 Wellington (NZ). **WHITE, Madeleine**; 17 Toru Street, Lyall Bay, 6022 Wellington (NZ).

(74) Agent: **AJ PIETRAS IP LTD**; Level 2, 46-50 Bloomfield Terrace, 5010 Lower Hutt (NZ).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UY, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

(54) Title: TREATMENT FOR HEMANGIOMA

(57) Abstract: The invention relates to a medicament or method for topically treating hemangioma, comprising, or administering, Propranolol and Fosinopril in a molar ratio of 2 to 0.9 - 1.3 respectively. The invention also relates to the use of Propranolol and Fosinopril in the manufacture of a medicament for topical administration to a human patient for treating hemangioma, where the Propranolol and Fosinopril are in a molar ratio of 2 to 0.9 - 1.3.

WO 2025/221153 A1